REGULATORY

MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake

July 30, 2026

Japan’s health ministry has asked five industry organizations, including the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ), to take steps to ensure the stable supply of pharmaceuticals and medical devices following the Kumamoto earthquake.

The Ministry of Health, Labor and Welfare (MHLW) issued an administrative communication to the five organizations on July 28, saying it will monitor local supply and demand conditions for pharmaceuticals and medical devices and take any necessary measures. It also asked the organizations to provide active support if requested by the ministry.

The notice was sent to the FPMAJ, the Federation of Japan Pharmaceutical Wholesalers Association (JPWA), the Japan Federation of Medical Devices Associations, the Japan Association of Health Industry Distributors, and the Japan Industrial and Medical Gases Association.

Related Article

REGULATORY

By Shinya Sato

Japan’s push to expand biosimilar use is running into a troubling supply problem. All seven ingredients that made their biosimilar…

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

By Hayate Horiguchi

Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…

By Shunsuke Tani

Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…